Clinical Remission in Severe Asthma: A Pooled Post hoc Analysis of the Patient Journey with Benralizumab

Andrew Menzies-Gow,[1] Flavia L. Hoyte,[2] David B. Price,[3,4] David Cohen,[5] Peter Barker,[5] James Kreindler,[5] Maria Jison,[5] Christopher L. Brooks,[6] Peggy Papeleu,[7] Rohit Katial[5]

[1]Royal Brompton and Harefield Hospitals, London, UK; [2]Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health, Denver, Colorado, USA; [3]Observational and Pragmatic Research Institute, Midview City, Singapore; [4]Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; [5]BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA; [6]BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; [7]AstraZeneca, Groot-Bijgaarden, Belgium.

Corresponding author:
Andrew Menzies-Gow, PhD,
Department of Respiratory Medicine,
Royal Brompton Hospital, Sydney St,
London SW3 6NP, United Kingdom.
E-mail: a.menzies-gow@rbht.nhs.uk.

Supplementary Table 1. Percentages of patients in SIROCCO achieving composite remission components[a] after 6 months and 12 months[b] according to baseline blood eosinophil levels.

Patients, % (n/N)	6 months Benra Q8W	6 months Placebo	12 months Benra Q8W	12 months Placebo
No exacerbations, no OCS use				
All patients	72.1 (217/301)	63.0 (206/327)	61.1 (179/293)	48.9 (153/313)
≥150 eosinophils/μL	73.0 (184/252)	62.2 (163/262)	60.9 (151/248)	50.4 (127/252)
≥300 eosinophils/μL	73.6 (145/197)	59.7 (132/221)	63.5 (122/192)	49.3 (104/211)
No exacerbations, no OCS use, pre-BD FEV_1 increase ≥100 mL				
All patients	44.2 (133/301)	34.9 (114/327)	36.2 (106/293)	24.9 (78/313)
≥150 eosinophils/μL	46.4 (117/252)	34.7 (91/262)	37.1 (92/248)	27.0 (68/252)
≥300 eosinophils/μL	48.7 (96/197)	36.2 (80/221)	40.6 (78/192)	28.9 (61/211)
No exacerbations, no OCS use, ACQ-6 <1.5				
All patients	38.5 (116/301)	27.2 (89/327)	36.5 (107/293)	23.0 (72/313)
≥150 eosinophils/μL	38.9 (98/252)	29.0 (76/262)	34.7 (86/248)	25.8 (65/252)
≥300 eosinophils/μL	41.1 (81/197)	27.6 (61/221)	38.0 (73/192)	25.6 (54/211)
No exacerbations, no OCS use, ACQ-6 ≤0.75				
All patients	22.6 (68/301)	16.2 (53/327)	20.1 (59/293)	11.8 (37/313)
≥150 eosinophils/μL	22.6 (57/252)	16.8 (44/262)	20.2 (50/248)	12.3 (31/252)
≥300 eosinophils/μL	23.9 (47/197)	17.2 (38/221)	23.4 (45/192)	12.3 (26/211)
No exacerbations, no OCS use, ACQ-6 <1.5, pre-BD FEV_1 increase ≥100 mL				
All patients	24.6 (74/301)	17.1 (56/327)	21.8 (64/293)	13.7 (43/313)
≥150 eosinophils/μL	26.2 (66/252)	17.6 (46/262)	21.8 (54/248)	16.3 (41/252)
≥300 eosinophils/μL	27.9 (55/197)	17.2 (38/221)	24.0 (46/192)	16.6 (35/211)
Clinical remission				
All patients	15.0 (45/301)	11.0 (36/327)	13.3 (39/293)	6.4 (20/313)
≥150 eosinophils/μL	15.9 (40/252)	11.5 (30/262)	13.7 (34/248)	7.1 (18/252)
≥300 eosinophils/μL	16.2 (32/197)	12.2 (27/221)	15.6 (30/192)	7.6 (16/211)

ACQ-6, Asthma Control Questionnaire, 6-item; benra Q8W, benralizumab every 8 weeks; FEV_1, forced expiratory volume in 1 second; OCS, oral corticosteroids.

[a]Components of response include no exacerbations, no OCS use, ACQ-6 score <1.5 or ≤0.75, and pre-BD FEV_1 increase ≥100 mL.

[b]N includes all patients still in the study at visit closest to timepoint. 6 months = Week 24 (SIROCCO); 12 months = Week 48 (SIROCCO).

Supplementary Table 2. Percentages of patients in CALIMA achieving composite remission components[a] after 6 months and 12 months[b] according to baseline blood eosinophil levels.

Patients, % (n/N)	6 months Benra Q8W	6 months Placebo	12 months Benra Q8W	12 months Placebo
No exacerbations, no OCS use				
All patients	74.0 (228/308)	67.4 (213/316)	61.4 (180/293)	50.2 (154/307)
≥150 eosinophils/μL	74.2 (198/267)	68.7 (191/278)	62.6 (159/254)	51.1 (138/270)
≥300 eosinophils/μL	73.8 (152/206)	68.4 (147/215)	61.0 (122/200)	51.9 (107/206)
No exacerbations, no OCS use, pre-BD FEV_1 increase ≥100 mL				
All patients	46.1 (142/308)	34.2 (108/316)	38.9 (114/293)	25.1 (77/307)
≥150 eosinophils/μL	47.9 (128/267)	35.3 (98/278)	41.7 (106/254)	26.3 (71/270)
≥300 eosinophils/μL	50.0 (103/206)	36.7 (79/215)	41.5 (83/200)	28.2 (58/206)
No exacerbations, no OCS use, ACQ-6 <1.5				
All patients	42.2 (130/308)	33.9 (107/316)	36.2 (106/293)	26.7 (82/307)
≥150 eosinophils/μL	41.9 (112/267)	35.3 (98/278)	38.2 (97/254)	27.4 (74/270)
≥300 eosinophils/μL	45.1 (93/206)	34.9 (75/215)	40.0 (80/200)	29.1 (60/206)
No exacerbations, no OCS use, ACQ-6 ≤0.75				
All patients	22.7 (70/308)	14.9 (47/316)	21.1 (62/293)	15.0 (46/307)
≥150 eosinophils/μL	23.6 (63/267)	15.8 (44/278)	22.8 (58/254)	15.9 (43/270)
≥300 eosinophils/μL	25.2 (52/206)	16.7 (36/215)	25.0 (50/200)	17.0 (35/206)
No exacerbations, no OCS use, ACQ-6 <1.5, pre-BD FEV_1 increase ≥100 mL				
All patients	27.9 (86/308)	20.9 (66/316)	25.9 (76/293)	16.0 (49/307)
≥150 eosinophils/μL	29.6 (79/267)	21.9 (61/278)	28.3 (72/254)	16.7 (45/270)
≥300 eosinophils/μL	33.0 (68/206)	24.2 (52/215)	29.5 (59/200)	18.4 (38/206)
Clinical remission				
All patients	14.6 (45/308)	11.1 (35/316)	15.7 (46/293)	9.1 (28/307)
≥150 eosinophils/μL	15.7 (42/267)	12.2 (34/278)	16.9 (43/254)	10.4 (28/270)
≥300 eosinophils/μL	17.5 (36/206)	14.0 (30/215)	18.0 (36/200)	12.6 (26/206)

ACQ-6, Asthma Control Questionnaire, 6-item; benra Q8W, benralizumab every 8 weeks; FEV_1, forced expiratory volume in 1 second; OCS, oral corticosteroids.

[a]Components of response include no exacerbations, no OCS use, ACQ-6 score <1.5 or ≤0.75, and pre-BD FEV_1 increase ≥100 mL.

[b]N includes all patients still in the study at visit closest to timepoint. 6 months = Week 24 (CALIMA); 12 months = Week 56 (CALIMA).

Supplementary Table 3. Percentages of patients in ZONDA achieving composite remission components[a] after 6 months[b] according to baseline blood eosinophil levels.

Patients, % (n/N)	6 months Benra Q8W	6 months Placebo
No exacerbations, no OCS use		
All patients	57.5 (23/40)	17.5 (7/40)
≥150 eosinophils/μL	57.5 (23/40)	17.5 (7/40)
≥300 eosinophils/μL	55.6 (20/36)	20.6 (7/34)
No exacerbations, no OCS use, pre-BD FEV_1 increase ≥100 mL		
All patients	35.0 (14/40)	17.5 (7/40)
≥150 eosinophils/μL	35.0 (14/40)	17.5 (7/40)
≥300 eosinophils/μL	36.1 (13/36)	20.6 (7/34)
No exacerbations, no OCS use, ACQ-6 <1.5		
All patients	47.5 (19/40)	10.0 (4/40)
≥150 eosinophils/μL	47.5 (19/40)	10.0 (4/40)
≥300 eosinophils/μL	47.2 (17/36)	11.8 (4/34)
No exacerbations, no OCS use, ACQ-6 ≤0.75		
All patients	30.0 (12/40)	7.5 (3/40)
≥150 eosinophils/μL	30.0 (12/40)	7.5 (3/40)
≥300 eosinophils/μL	30.6 (11/36)	8.8 (3/34)
No exacerbations, no OCS use, ACQ-6 <1.5, pre-BD FEV_1 increase ≥100 mL		
All patients	32.5 (13/40)	10.0 (4/40)
≥150 eosinophils/μL	32.5 (13/40)	10.0 (4/40)
≥300 eosinophils/μL	33.3 (12/36)	11.8 (4/34)
Clinical remission		
All patients	22.5 (9/40)	7.5 (3/40)
≥150 eosinophils/μL	22.5 (9/40)	7.5 (3/40)
≥300 eosinophils/μL	22.2 (8/36)	8.8 (3/34)

ACQ-6, Asthma Control Questionnaire, 6-item; benra Q8W, benralizumab every 8 weeks; FEV_1, forced expiratory volume in 1 second; OCS, oral corticosteroids.

[a]Components of response include no exacerbations, no OCS use, ACQ-6 score <1.5 or ≤0.75, and pre-BD FEV_1 increase ≥100 mL.

[b]N includes all patients still in the study at visit closest to timepoint. 6 months = Week 28 (ZONDA).

Supplementary Figure 1. Patient populations from predecessor clinical trials through the post hoc analysis.



Benra Q8W, benralizumab every 8 weeks.